Zerodha faces investors’ flurry on technical glitch, BFSI News, ET BFSI

[ad_1]

Read More/Less


New Delhi: Users of online brokerage Zerodha faced difficulty in trading on Wednesday due to a technical glitch on its trading platform. The brokerage house faced customers’ ire on microblogging site Twitter as they complained that prices and trading froze on its platform during the trading hours.

“Zerodha down, price not updating,” one user tweeted.

Another user mentioned, “Zerodha is not working at the peak time of trading. Prices are stuck.”

“Because of Zerodha, I suffer a loss of Rs 80,000 in ONGC. Zerodha app was stuck. I sold my holding for intraday and stock runs like a wild horse from 65 to 82 within 5 min & came down to 62. I was trying to exit my position but thanks to Zerodha, my stock was sold. Buying price 148,” a user tweeted.

On October 18, investors of several brokerage houses, including Zerodha and Paytm Money, had faced possible difficulty while selling shares due to “an issue” related to Central Depository Services India Limited (CDSL).

Founded in 2010, Zerodha Broking is a financial services company that offers retail as well as institutional broking, currencies and commodities trading, mutual funds, and bonds.

Over 7.5 million clients place millions of orders every day through its platform, contributing more than 15 per cent of all Indian retail trading volumes.



[ad_2]

CLICK HERE TO APPLY

Green Economy Stocks To Buy In 2022: Morgan Stanley

[ad_1]

Read More/Less


GAIL India

GAIL India’s Current Market Price is ~ Rs. 141, till November 18, 1.38 PM IST. Morgan Stanley has given a Price target of Rs. 202 for the same company’s stock. The firm thinks that the company will work for hand in hand for the rising gas penetration in India. GAIL India will also help the central government to focus on expanding gas as one major energy transition fuel.

National Thermal Power Corporation Limited (NTPC)

National Thermal Power Corporation Limited (NTPC)

NTPC’s Current Market Price is ~ Rs. 136, till November 18, 1.38 PM IST. Morgan Stanley has given a Price target of Rs. 150 for the same company’s stock. The firm thinks that this public sector corporation will transform for becoming an integrated player in the diversified sectors in major segments like renewable energy, energy storage, energy distribution, and EV charging.

Reliance Industries Ltd.

Reliance Industries Ltd.

Reliance Industries’ Current Market Price is ~ Rs. 2484, till November 18, 1.43 PM IST. Morgan Stanley has given a Price target of Rs. 2,925 for the same company’s stock. The firm thinks that Reliance Industries is focused on the de-carbonization of its energy business including infrastructure in areas of hydrogen, integrated solar PV, and grid batteries.

Larsen & Toubro

Larsen & Toubro

Larsen & Toubro’s Current Market Price is ~ Rs. 1912, till November 18, 1.55 PM IST. Morgan Stanley has given a Price target of Rs. 2,216 for the same company’s stock. Morgan Stanley believes that Larsen & Toubro is well concerned about de-carbonization in multiple segments of its own and also focussed to increase the green hydrogen portfolio, which contributed 31% of its revenue in FY21.

Motherson Sumi

Motherson Sumi

Motherson Sumi’s Current Market Price is ~ Rs. 240, till November 18, 1.55 PM IST. Morgan Stanley has given a Price target of Rs. 255, for the same company’s stock. The firm thinks that Motherson Sumi’s “wiring harness business will benefit from the industry’s product mix shifting towards hybrid cars and electric vehicles from internal combustion engines.”

Conference of Parties (COP)

Conference of Parties (COP)

Recently the Conference of Parties – COP26, the climate change summit has been organized in Glasgow. The stakeholders of the summit sounded optimistic about the green energy side, globally. The energy transition from fossil fuels to green or environment-friendly sources is the most important investment target of the current and the next decade. Morgan Stanley in its report stated, “With COP26 wrapped up in November, we expect 2022 will be a year of implementation rather than seeing new policies and targets.”



[ad_2]

CLICK HERE TO APPLY

Worldline launches cross-border solution for online businesses, BFSI News, ET BFSI

[ad_1]

Read More/Less


Worldline has launched a cross-border solution designed for international online businesses to expand their e-commerce presence in India.

The solution suite enables processes in India, without requirement for a local entity, and will be available early next year.

Ramesh Narasimhan, Head of Digital Commerce India at Worldline says, “India is a crucial market for Worldline alongside other BRIC economies. Worldline is best placed to make that digital transformation opportunity as seamless as possible.”

The solution will provide access to mandated and popular local payment methods namely: RuPay, UPI and UPI QR and Netbanking. Merchants can list their services in INR to consumers via these payment methods.

It will also repatriate funds, specifically enabling cross-border settlement of funds in the merchant’s preferred currency.

Follow and connect with us on , Facebook, Linkedin



[ad_2]

CLICK HERE TO APPLY

‘Buy’ This Infra Stock For 52.4% Upside With A CMP Of Rs. 103: HDFC Securities

[ad_1]

Read More/Less


Company performance

Ashoka Buildcon (ASBL)’s revenue was Rs. 9.2bn (+5%/-9% YoY/QoQ), EBITDA stood at Rs. 1.05bn (-19% YoY, -12% QoQ), with an EBITDA margin at 11.5% (-244/-265 bps YoY/QoQ). The company additionally reported a PAT of Rs. 0.9bn. The company’s execution was subdued, largely on account of the monsoon. Including the recently-won orders, the order book (OB) stands at Rs. 120bn. The company has reduced its FY22 revenue growth guidance from 25% to 20%. The SBI Macquarie deal was renegotiated earlier in Oct-21 for consideration of a minimum of Rs. 11bn, with Dec-21 as the deadline for completion.

Comments by HDFC Securities

Comments by HDFC Securities

According to HDFC Securities, the company had a “Subdued quarter. We maintain BUY and cut our EPS along with TP to Rs. 157 (9x Sep-23E EPS), given the cut in guidance and higher share in the mix from EPC orders vs HAM. This may lower the EBITDA margin as HAM projects have higher margins.”

About the company

About the company

Ashoka Buildcon is a leading construction and highway developer in India. Ashoka Buildcon is an integrated EPC, BOT & HAM player in the country, with a portfolio of a major 39 PPP projects. The company has operated in more than 20 states across India, completing projects for Central and State Governments.

Disclaimer

Disclaimer

The above stock was picked from the brokerage report of HDFC Securities. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

HDFC Securities Recommends To ‘Buy’ This Stock For 15% Return

[ad_1]

Read More/Less


Target Price

The Current Market Price (CMP) of Ahluwalia Contracts is Rs. 450. The brokerage firm, HDFC Securities has estimated a Target Price for the stock at Rs. 519. Hence the stock is expected to give a 15% return, in a Target Period of 1 year.

Stock Outlook
Current Market Price (CMP) Rs. 450
Target Price Rs. 519
1 year return 15.00%

Company performance

Company performance

“Ahluwalia Contracts (AHLU) reported a revenue/EBITDA/APAT beat of 24/(1.1)/(1.4)%. Whilst execution normalized since the start of Q2FY22, commodity price volatility negatively impacted margins,” the brokerage firm informs. Given robust execution, AHLU has increased the earlier 15-20% revenue growth guidance for FY22 to 20-25% and, given benign commodity prices, it lowered 11-12% EBITDA margin guidance to ~10%. The NWC days reduced to 91, from 107 in Q1FY22.

Comments by HDFC Securities

Comments by HDFC Securities

According to HDFC Securities, “Given robust order book (OB) and execution, we have increased our estimates for FY22/23/24. We maintain Buy with an increased TP of Rs. 519 (13x multiple; Sep-23E EPS), given the robust OB, net cash balance sheet, and better RoE/RoCE than peers. We expect the uptick in growth and margin expansion to continue through H2 FY22 as Covid-19 headwinds recede.”

About the company

About the company

With specialized experience in the Construction Industry for more than 40 years, Ahluwalia Contracts, have carved a niche in the industry. Their turnover was over Rs. 1982.19 Crores for the FY 2020-21. they have worked for some of the most recognized commercial and institutional projects. They are also associated with ITC hotels and AIMS hospitals for construction.

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of HDFC Securities. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

But This Construction Stock For +21% Upside Suggested By IDBI Capital

[ad_1]

Read More/Less


Q2FY22 results of IRCON

In its research report, the brokerage has stated that “IRCON international (IRCON) Q2FY22 PAT came 10% higher than our estimate. This is led by higher other income. H1FY22 revenue increased by 71% YoY and IRCON targets FY22E Revenue at ~Rs60-70bn but expects softness in margin. Based on guidance, H2FY22 implies revenue to increase by 1% to 29% YoY. But due to the expectation of weak margin we have cut EPS for FY22E/23E by 9%/10% (exhibit 8). H1FY22 Order book at Rs349bn provides revenue visibility at 6x TTM Revenue. YTDFY22 order inflow (won on competitive bidding) is at Rs27bn and additionally, the company emerged as L-1 bidder in a project worth Rs86bn. We have rolled forward TP to FY24E at Rs58, valued at PER of 10x (earlier Rs56). Company has announced a second interim dividend of Rs0.7/sh (first was Rs0.45/sh). We have modeled a total dividend of Rs2.9 for FY22E (implying div. yield of 6%). Maintain BUY rating on the stock.”

Key highlights and investment rationale for IRCON international (IRCON) according to IDBI Capital

Key highlights and investment rationale for IRCON international (IRCON) according to IDBI Capital

Q2FY22 Snapshot: IRCON Revenue was up 47% YoY at Rs14bn. EBITDA stood at Rs1bn (+49% YoY/ +39% QoQ) with EBITDA margin at 6.9%. Q2FY22 PAT at Rs1.3bn (+74% YoY, +57% QoQ). This is led by higher other income at Rs0.8bn vs Rs0.5bn YoY. Segment-wise, Domestic EBIT margin was higher QoQ/ YoY. But International EBIT was at loss due to a one-off.

L1 in Rs86bn project: H1FY22 IRCON’s Order book stood at Rs349bn equals 6x TTM Revenue with 88%/ 5%/ 7% of order book from Railway/ Highway/ Other. In other, it has a solar power segment worth Rs26bn via e-Reverse auction with a Viability Gap Funding (VGF). Equity investment in solar project is expected at Rs4bn and IRCON has the option to unlock the value at IRR of 14%. Geography wise international order book at 4% and domestic at 96%.

FY22E PAT guidance at Rs4.8bn: IRCON targets FY22E Revenue/ PAT at ~Rs60-70bn/ Rs4.8bn. And PAT margin is expected at 8-9% for H2FY22. Company re-iterated it’s FY23E revenue target of Rs100bn.

Disclaimer

Disclaimer

The above is picked from the brokerage report of IDBI Capital. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

Small finance banks, microlenders stay away from IPO party, BFSI News, ET BFSI

[ad_1]

Read More/Less


Kolkata: While Nykaa, Paytm and Policybazaar are the toast of the primary equity market now, lenders to the bottom of the pyramid which had earlier lured investors for their capacity to earn high margins remain laggards.

Half-a-dozen entities in the small finance bank and microfinance space that have received approval for raising funds through initial public offerings appear to be going slow because of valuation issues, people familiar with the matter said.

Among small finance banks, ESAF, Jana, Fincare and Utkarsh are said to be weighing investor interest for their proposed IPOs. Utkarsh Small Finance Bank received Securities & Exchange Board of India’s approval for IPO in June, Jana SFB got it in July and Fincare in August. ESAF Small Finance Bank received the regulator’s approval in October for the second time, after the one-year validity on the first lapsed in March.

Microfinance firm Arohan Financial Services received Sebi approval in April but has yet to hit the market. Northern Arc Capital, a non-bank lender with exposure to the financial inclusion space, got the approval in September.

“Many Lenders including those in the microfinance industry are not getting the kind of investor interest or valuation seen for primary issues of fintech firms,” said Donald D’Souza, managing director & co-head (investment banking) at Equirus.

“Some of these firms have done a few roadshows but have failed to attract investors at higher valuation. That’s the reason why some of these lenders are not seen in the IPO market despite the bull run. Even some small finance banks, which need to be listed within a specified time frame to meet regulations, are yet to be seen in this space,” D’Souza said.

Investors are apparently exercising caution as micro lenders are saddled with concerns over asset quality, high credit cost and squeezed margin following the pandemic-led stress on their borrowers.

The portfolio at risk for 30 days (PAR30+) for the microfinance sector remained high at 10.18% at the end of September, even after showing a sharp improvement from 16.56% three months earlier.

“The new-age companies are mostly making merry in the season of IPOs since investors are ready to pay huge premiums for new business models and fresh ideas. The party is on at least till Christmas. The valuations however are relatively muted for lending companies as investors are comparing them with the existing secondary market prices in the same segment,” said Dinesh Arora, partner and leader (deals) at PwC India.

As many as 52 companies have mobilised Rs 1.08 lakh crore from primary issuances in 2021 so far compared with Rs 26,600 crore raised by 15 companies last year. Foreign portfolio investors are said to have invested more than Rs 46,000 crore in IPOs this year.

Microfinance association Sa-Dhan said the average collection efficiency has increased to more than 95% in the quarter through September from 85% in the preceding quarter, even as 13 states and union territories including Chhattisgarh, Kerala, Tamil Nadu and West Bengal have their PAR30+ value higher than the industry average.



[ad_2]

CLICK HERE TO APPLY

2 Stocks To Buy From IDBI Capital For Good Returns of +24% to +25%

[ad_1]

Read More/Less


2QFY22 results of Britannia Industries

IDBI Capital in its research has said that “Britannia (BRIT) 2QFY22 result was below our estimates. Revenue growth at 6%YoY on a high base of 12% is healthy. However, a steep contraction in gross margin led to a higher than expected decline in PAT. Positively, BRIT expects to offset the impact of inflation both by taking price hikes (to the tune of 1/3rd) and grammage reduction (2/3rd) by the end of FY22. During 2QFY22 BRIT has taken a 4% price hike and expects benefit from grammage reduction to flow in 2HFY22.”

The brokerage has also clarified that “Distribution expansion is tracking well. BRIT expects rural to outperform urban through distribution expansion and penetration. In rural; market share gains stood at 2.5x vs urban during 2QFY22. Modern trade grew 10% higher than traditional channels. However, the company expects lower volume growth due to inflation and reduction in grammage during 2HFY22.”

Key highlights and investment rationale for Britannia Industries according to IDBI Capital

Key highlights and investment rationale for Britannia Industries according to IDBI Capital

Domestic business remained resilient: Consolidated revenue grew 6%YoY (on a base of 12%YoY in 2QFY21) driven by 6%YoY growth in the domestic business while revenue from subsidiaries (consolidated less standalone) declined 5%YoY. BRIT has taken a 4% price hike during the quarter. In the international market; Nepal grew in high double digits led by market share gains.

Inflationary raw material impacts operating margins: Gross margin contracted 502bp to 37.5% driven by material inflation in palm oil (54%YoY), industrial fuel (35% YoY) and packaging material (30%YoY). EBITDA declined 17%YoY to Rs 5.6bn. A decline in Adjusted PAT at 23%YoY is higher due to Rs 350mn tax benefit in the base quarter.

Maintain BUY: As per the revised business outlook on inflation; we have trimmed our EPS estimate by 6- 13% in FY22-23E. We have introduced FY24E in our estimates. We maintain our bullish view on the company. Our revised TP stands at Rs 4507 with a BUY rating.

Q2FY22 results of RITES

Q2FY22 results of RITES

According to the brokerage’s research report “RITES (RITE) Q2FY22, PAT came 14%/ 20% higher than our / consensus estimate. Beat in the result is led by better execution (revenue) in the Export segment, as shipment of the orders has commenced. Here revenue stood at Rs3410mn vs Rs7mn QoQ vs nil YoY, RITE expects its FY22E revenue and PAT to reach FY20 levels and FY23E to witness growth in the business. Q2FY22 order inflow is at Rs2.6bn and Order book at Rs64bn equals 3x TTM Revenue.”

IDBI Capital has stated in its research report that “RITE has announced a second interim dividend of Rs4/sh for FY22 and till date dividend announced is at Rs6 for FY22. We have introduced FY24E financials and rolled forward TP to FY24E at Rs369 (valued at 12x PER). Maintain BUY rating on the valuation (trades at its historical average at 10x FY24E EPS) and a dividend yield of 7-8%.”

Key highlights and investment rationale for RITES according to IDBI Capital

Key highlights and investment rationale for RITES according to IDBI Capital

Q2FY22 Snapshot: Q2FY22 Revenue stood at Rs7.6bn (+72%YoY / +113% QoQ). This is led by better higher Exports revenue at Rs3.4bn vs Rs7mn QoQ. Consultancy / Leasing execution was up 5% /22% YoY at Rs2.6bn / Rs0.3bn. Consolidated EBITDA margin stood at 28.6% vs 29% YoY and was higher QoQ of 27.3%. EBITDA increased by 69% YoY at Rs2.1bn. PAT stood at Rs1.7bn (+32% YoY / +124% QoQ).

Order book provided visibility: H1FY22 Order book is at Rs64bn (equals 3x TTM Revenue) comprising of Consultancy /Exports/ Lease/ Turnkey/ REMC at Rs2.5bn /Rs10bn/ Rs1bn/ Rs28bn/ Rs1bn. New opportunity is expected from metro consultancy order and 2-3 international orders of USD100mn each.

Segmental composition: With Exports back on track, RITE is aiming for Rs7-7.5bn revenue in FY22E. Consultancy segment is growing and RITE expects revenue to increase at 10% pa over the next 3-4 years. For Turnkey segment, the company expects revenue to improve on QoQ and stabilize in Q4FY22. Going forward, the company is targeting to improve margins at ~3% for turnkey.

Disclaimer

Disclaimer

The above stocks are picked from the brokerage report of IDBI Capital. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

Buy This Large Cap Stock With Upside Potential Up To 25%: ICICI Securities

[ad_1]

Read More/Less


NMDC: Q2FY22 Results

In Q2FY22, NMDC reported a strong performance.

  • NMDC reported iron ore sales volume of 9.0 million tonnes (MT) in the third quarter, up 36% year over year but down 5% quarter over quarter (in line with our expectation of 8.9 million tonnes). EBITDA/tonne was Rs 3488/tonne, exceeding our forecast of Rs 3000/tonne Rs 4421/tonne in Q1FY22).
  • Revenue from operations for the quarter was Rs 6794 crore, up 205 percent year over year and 4 percent quarter over quarter, exceeding our forecast of Rs 5944 crore. EBIDTA for the quarter was Rs 3115 crore, up 202 percent year over year but down 25 percent quarter over quarter, exceeding our forecast of Rs 2679 crore.

NMDC: Target and Valuation

NMDC: Target and Valuation

“NMDC’s share price has given a return of ~54% over the last 12 months (from ~| 91 in November 2020 to ~| 140 in November 2021). We maintain our BUY rating on the stock Target Price and Valuation: We value NMDC at Rs 175, based on SoTP valuation,” the brokerage has said.

Key triggers for future price-performance:

The Nagarnar steel factory is expected to be operational in Q4FY22, according to NMDC. NMDC has provided volume guidance of 44 MT for FY22E. NMDC has set a capex budget of Rs 3750 crore for FY22E.

Alternate Stock Idea

The brokerage also favours Hindalco in their metal sector coverage. Hindalco is the world’s largest aluminium corporation in terms of sales, as well as a major copper player. BUY with a Rs600 target price

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of ICICI Direct. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

This Pharma Stock Is Given A ‘Buy’ By ICICI Direct For 21% Gains In 12 Months

[ad_1]

Read More/Less


Buy IPCA Laboratories for a price target of Rs. 2490

The fully integrated pharma entity manufactures more than 350 formulations and 80 APIs. In Fy21, exports accounted for 50% of the company’s revenues. The company’s leading therapeutic domains cover pain management, cardiovascular and anti-diabetics, anti-infectives, anti-malarials that on a whole contribute to 75% revenues.

Q2FY22 Results:

Q2FY22 Results:

Despite the challenges the company reported a decent September quarter of Fy22 period. Sales came in higher by 13.5% YoY to Rs. 1544.4 crore. EBITDA also registered a surge of 1.5% YoY at Rs. 365.6 crore

with margins at 23.7%.Furthermore, PAT was at Rs. 250.2 crore (down 6.3% YoY).

Target Price and Valuation:

Target Price and Valuation:

We value Ipca at Rs. 2490 i.e. 26x P/E on FY23E EPS. “We Maintain BUY due to good traction in domestic formulations and sustainable growth amid some margin pressure in medium term”, says the brokerage.

Key triggers for future price performance:

• Incremental growth in other therapies (excluding malaria), especially non-communicable diseases like pain management, cardio-diabetology, etc, the

overall portfolio is poised for steady growth.

• Sustained traction from branded and generics exports sales with a revival in EU is likely to mitigate the US void.

• Commissioning of Devas plant and additional capacities from Ratlam.

• US traction will take longer due to USFDA import alerts for the Ratlam facility that is the only API source for Silvassa and Pithampur formulations.

Alternate Stock Idea:

Alternate Stock Idea:

Besides Ipca, in the healthcare segment, ICICI Direct likes Ajanta Pharma. “Ajanta Pharma is a focused player in branded, which constitutes appx.70% of overall sales that are spread across geographies including India. Focus is launching maximum number of first time launches with new drug delivery system (NDDS)”, says the brokerage house. The company recommends buying Ajanta with target price of Rs. 2500, implying returns of 18 percent as against the last traded price of Rs. 2120.

Disclaimer:

Disclaimer:

The above stock has been picked from the brokerage report of ICICI Direct. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

1 24 25 26 27 28 387